0001062993-21-007983.txt : 20210826 0001062993-21-007983.hdr.sgml : 20210826 20210826192953 ACCESSION NUMBER: 0001062993-21-007983 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210824 FILED AS OF DATE: 20210826 DATE AS OF CHANGE: 20210826 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McIlwain Matthew S CENTRAL INDEX KEY: 0001381752 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39434 FILM NUMBER: 211213773 MAIL ADDRESS: STREET 1: 1000 SECOND AVENUE STREET 2: SUITE 3700 CITY: SEATTLE STATE: WA ZIP: 98104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nautilus Biotechnology, Inc. CENTRAL INDEX KEY: 0001808805 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 425 PONTIUS AVE N, STE 202 CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-333-2001 MAIL ADDRESS: STREET 1: 425 PONTIUS AVE N, STE 202 CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp III DATE OF NAME CHANGE: 20200408 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0306 4 2021-08-24 0001808805 Nautilus Biotechnology, Inc. NAUT 0001381752 McIlwain Matthew S C/O MADRONA VENTURE GROUP 999 THIRD AVENUE, 34TH FLOOR SEATTLE WA 98104 1 0 0 0 Common Stock 2021-08-24 4 P 0 13568 7.6849 A 335673 D Common Stock 2021-08-25 4 P 0 11693 7.7361 A 347366 D Common Stock 2021-08-26 4 P 0 11709 7.7132 A 359075 D Common Stock 5798394 I By Madrona Venture Fund VI, LP Common Stock 222376 I By Madrona Venture Fund VI-A, LP The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.56 to $7.75, inclusive. The reporting person undertakes to provide to Nautilus Biotechnology, Inc., any security holder of Nautilus Biotechnology, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.69 to $7.75, inclusive. The reporting person undertakes to provide to Nautilus Biotechnology, Inc., any security holder of Nautilus Biotechnology, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.67 to $7.75, inclusive. The reporting person undertakes to provide to Nautilus Biotechnology, Inc., any security holder of Nautilus Biotechnology, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Shares held by Madrona Venture Fund VI, LP ("Madrona Fund VI"). Madrona Investment Partners VI, L.P. ("Madrona Partners VI") is the general partner of Madrona Fund VI, and Madrona VI General Partner, LLC ("Madrona VI LLC") is the general partner of Madrona Partners VI. The reporting person, is a managing member of Madrona VI LLC. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Shares held by Madrona Venture Fund VI-A, LP ("Madrona Fund VI-A"). Madrona Partners VI is the general partner of Madrona Fund VI-A, and Madrona VI LLC is the general partner of Madrona Partners VI. The reporting person, is a managing member of Madrona VI LLC. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of benefical ownership of all of the reported shares for purposes of Section 16 or for any other purpose. /s/ Matt McIlwain 2021-08-26